 |
PDBsum entry 6hv5
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
250 a.a.
|
 |
|
|
|
|
|
|
|
244 a.a.
|
 |
|
|
|
|
|
|
|
240 a.a.
|
 |
|
|
|
|
|
|
|
235 a.a.
|
 |
|
|
|
|
|
|
|
231 a.a.
|
 |
|
|
|
|
|
|
|
243 a.a.
|
 |
|
|
|
|
|
|
|
241 a.a.
|
 |
|
|
|
|
|
|
|
226 a.a.
|
 |
|
|
|
|
|
|
|
204 a.a.
|
 |
|
|
|
|
|
|
|
195 a.a.
|
 |
|
|
|
|
|
|
|
212 a.a.
|
 |
|
|
|
|
|
|
|
222 a.a.
|
 |
|
|
|
|
|
|
|
233 a.a.
|
 |
|
|
|
|
|
|
|
196 a.a.
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
References listed in PDB file
|
 |
|
Key reference
|
 |
|
Title
|
 |
Structure-Based design of inhibitors selective for human proteasome β2c or β2i subunits.
|
 |
|
Authors
|
 |
B.T.Xin,
E.M.Huber,
G.De bruin,
W.Heinemeyer,
E.Maurits,
C.Espinal,
Y.Du,
M.Janssens,
E.S.Weyburne,
A.F.Kisselev,
B.I.Florea,
C.Driessen,
G.A.Van der marel,
M.Groll,
H.S.Overkleeft.
|
 |
|
Ref.
|
 |
J Med Chem, 2019,
62,
1626-1642.
[DOI no: ]
|
 |
|
PubMed id
|
 |
|
 |
 |
|
Abstract
|
 |
|
Subunit-selective proteasome inhibitors are valuable tools to assess the
biological and medicinal relevance of individual proteasome active sites.
Whereas the inhibitors for the β1c, β1i, β5c, and β5i subunits exploit the
differences in the substrate-binding channels identified by X-ray
crystallography, compounds selectively targeting β2c or β2i could not yet be
rationally designed because of the high structural similarity of these two
subunits. Here, we report the development, chemical synthesis, and biological
screening of a compound library that led to the identification of the β2c- and
β2i-selective compounds LU-002c (4; IC50 β2c: 8 nM, IC50
β2i/β2c: 40-fold) and LU-002i (5; IC50 β2i: 220 nM,
IC50 β2c/β2i: 45-fold), respectively. Co-crystal structures with
β2 humanized yeast proteasomes visualize protein-ligand interactions crucial
for subunit specificity. Altogether, organic syntheses, activity-based protein
profiling, yeast mutagenesis, and structural biology allowed us to decipher
significant differences of β2 substrate-binding channels and to complete the
set of subunit-selective proteasome inhibitors.
|
 |
|
|
|
|
 |